Resta O, Foschino M P, Maiorano V, Carniméo R, Carniméo N
Université de Bari (Italie) Chair de physiopathologie respiratoire.
Allerg Immunol (Paris). 1987 May;19(5):206-7, 209.
It is known that in some asthmatic subjects the administration of acetylsalicylic acid (ASA) and non-steroid anti-inflammatory drugs (NSAID) results in bronchodilatation. We have administered 750 mg of ASA intravenously to 100 asthmatic patients who were without history of ASA intolerance. Functional assessment (FEV) was performed under basal conditions and after 5, 10, 15, 30, 60, 90, 120, 150 and 180 minutes after the administration of ASA. 64 patients had no functional variations, 14 showed a percentage variation of less than 20% in FEV and 14 had a doubtful bronchodilatation (FEV 15-20%). The test was repeated after an interval of 1 week in those patients who showed an increase of 20% in FEV and only 2 confirmed the bronchodilatation. The pathogenesis of asthma that is improved by ASA is not entirely clear, but it is an extremely interesting model for study of the role of different mediators in the asthma syndrome.
已知在一些哮喘患者中，给予乙酰水杨酸（ASA）和非甾体抗炎药（NSAID）会导致支气管扩张。我们对100名无ASA不耐受史的哮喘患者静脉注射了750毫克ASA。在基础条件下以及注射ASA后的5、10、15、30、60、90、120、150和180分钟进行了功能评估（FEV）。64名患者没有功能变化，14名患者的FEV百分比变化小于20%，14名患者有可疑的支气管扩张（FEV 15 - 20%）。在那些FEV增加20%的患者中，间隔1周后重复进行该测试，只有2名患者证实有支气管扩张。ASA改善哮喘的发病机制尚不完全清楚，但它是研究不同介质在哮喘综合征中作用的一个极其有趣的模型。
